Diligence memo · auto-generated · as of July 2, 2026
Cardioxyl Pharmaceuticals Inc
Cardioxyl Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cardioxyl Pharmaceuticals Inc operates in Pharmaceuticals, based in CHAPEL HILL.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cardioxyl Pharmaceuticals Inc has raised $52M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2012-10-24.
Most recent recorded round closed around 2012-10-24.
Valuation (modeled)modeled
Provath models Cardioxyl Pharmaceuticals Inc at approximately $954M (range $59M–$3.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.29× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 13.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 82% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.